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Summary In this phase II study, 39 women (median age 51 years) with advanced breast cancer received
docetaxel (75 mg m-2) intravenously over 1 h every 3 weeks as first-line chemotherapy for advanced disease,
without routine premedication for hypersensitivity reactions. In 31 evaluable patients, an overall response rate
of 52% (95% CI 33-70%) was achieved, including a complete response rate of 13%. The median time to first
response was 12 weeks (range 3-35+), the median duration of response was 34 weeks (range 11-42+) and
the median time to progression was 24 weeks (range 0-42+). Docetaxel showed considerable activity in
patients with visceral involvement (52% response), including lung (67%) and liver (44%) metastases. The safety
profile was acceptable. Grade 4 neutropenia occurred in 82% of patients (53% of cycles); febrile neutropenia
(grade 4 neutropenia with fever >38°C, requiring antibiotics) occurred in only three (7.7%) patients (1.4% of
cycles) and none of these required hospitalisation. Acute adverse events were generally well tolerated, with only
two grade 3 events and no grade 4 events reported. Despite no prophylactic premedication, the incidence of
acute hypersensitivity reactions was only 13%. Fluid retention was widely experienced (72% of patients) but
was severe in only five (12.8%) patients and was the reason for discontinuation of treatment in 16 patients.
Nevertheless, patients were able to receive a median cumulative dose of approximately 592 mg m-2 before
discontinuing treatment, and the syndrome was slowly reversible after treatment withdrawal. In conclusion,
docetaxel, even at a dose of 75 mg m-2, is confirmed to be an active agent in breast cancer. Compared with an
earlier study offirst-line docetaxel at the usual dose of 100 mg -2, it appears that 75 mg m-2 produces a lower
response rate (52% vs 68%), although this still compares favourably with that of doxorubicin monotherapy in
a similar patient population (43%). This difference is particularly striking in subgroups of patients with
particularly poor prognostic factors, such as liver metastases or involvement of more than two organs. The
incidence of fluid retention appears to be similar at the two doses and it is likely that premedication with
corticosteroids will be preferable to dose reduction for managing this adverse event.
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Breast cancer is the most common malignancy affecting
women and is the leading cause of death in western women
aged 40 to 55 years (McPherson et al., 1994; Harris et al.,
1993). In Europe, there are around 135 000 new cases of
breast cancer (24% of all cancer cases) and 58 000 deaths
caused by breast cancer (18% of all cancer deaths) annually
(Jensen et al., 1990).
The approach to the treatment of stage I and II breast
cancer has been considerably modified by the introduction of
adjuvant therapy with either cytotoxic or hormonal agents
(Fisher et al., 1975). However, despite these advances, 40-
60% of women with breast cancer will develop metastases
and ultimately die of their disease. The prognosis of
disseminated disease remains poor and median survival does
not exceed 24 months (Henderson, 1991; Hortobagyi and
Buzdar 1993). Many combinations of drugs have been
proposed to treat advanced disease: overall response rates
in the range of 40-80% have been reported, with complete
response rates of 10-20% (Harris et al., 1992; Henderson
1991). The median duration of response does not usually
exceed 1 year, although a small proportion of patients will
survive for longer than 5 years (Ross et al., 1985).
The highest response rates (55-80%) have been achieved
with anthracycline-based combinations such as cyclopho-
sphamide/doxorubicin/5-fluorouracil (CAF) (Henderson,
1991). However, the increasing use of anthracyclines in
adjuvant treatment in pre- and post-menopausal patients is
likely to limit their use in patients who subsequently relapse
and go on to develop advanced or metastatic disease
(Hortobagyi and Buzdar, 1993).
One therapeutic approach is to use dose-intensive
combination regimens of currently available drugs, and this
has resulted in promising preliminary results in phase II
studies, although this approach remains to be tested in phase
III trials (Williams et al., 1989; Antmann and Souhami,
1993). Another therapeutic approach is the use of new
chemotherapeutic agents with original mechanisms of action,
either as single agents or in combination regimens.
The taxoids paclitaxel (Taxolg, Bristol Myers Squibb,
Princeton, NJ, USA) and docetaxel (Taxoteres, Rhone-
Poulenc Rorer, Antony, France) represent a novel class of
antineoplastic drugs sharing a similar mechanism of action:
they promote microtubule assembly and inhibit the
depolymerisation of tubulin. This leads to the formation of
intracellular bundles of microtubules, which block cells in the
M-phase of the cell cycle, rendering them unable to divide.
This contrasts with the action of other spindle poisons in
clinical use such as colchicine or vinca-alkaloids which inhibit
tubulin assembly in microtubules (Bissery et al., 1991; Ringel
and Horwitz, 1991).
Docetaxel is a potent inhibitor of cell replication. The
activity of docetaxel has been demonstrated against a number
of freshly explanted and cloned human cancer specimens,
including breast cancers (Hanauske et al., 1992; Ringel and
Horwitz, 1991).
In preclinical studies, docetaxel was 2.5-fold more potent
than paclitaxel as an inhibitor of cell replication and 5-fold
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more potent than paclitaxel against paclitaxel-resistant cells
(Ringel and Horwitz 1991). In vivo, docetaxel was active in
both murine and human xenografted tumours. In a
comparative trial, docetaxel was 2.6-fold more active than
paclitaxel on B16 melanoma (Bissery et al., 1991).
In phase I dose-finding studies of docetaxel, the
maximum tolerated dose was 115 mg m-2 as a 1 h infusion
repeated every 3 weeks (Extra et al., 1993; Bisset et al.,
1993; Pazdur et al., 1992; Burris et al., 1993; De Valeriola et
al., 1992). Neutropenia was the dose-limiting toxicity. Oral
mucositis was associated with infusions of longer duration
(6 h, 24 h), and with frequently repeated infusions (daily for
5 days). Less frequently observed adverse effects were
hypersensitivity reactions, skin toxicity and peripheral
neurotoxicity.
The optimum dose of docetaxel for clinical use was
determined to be 100 mg m-2 given as a 1 h infusion every
3 weeks. At this dosage, phase II studies of docetaxel as
first-line chemotherapy have produced high response rates in
patients with advanced breast cancer. Preliminary results
have shown objective responses in 57-65% of evaluable
patients. (Chevallier et al., 1995; Seidman et al., 1993;
Trudeau et al., 1993). Results for duration of response and
time to progression are available for one of these studies
(Chevallier et al., 1995); in this study the median duration
of response was 44+ weeks and the median time to
progression 37+ weeks (Chevallier et al., 1995). Fluid
retention was a common finding in all three of these studies,
in which no routine premedication was given, and frequently
led to treatment discontinuation. The present study was
conducted in order to examine the efficacy and safety,
particularly the incidence and severity of fluid retention, of
docetaxel at the reduced dosage of 75 mg m-2 as a 1 h
infusion every 3 weeks, without prophylactic premedication
for hypersensitivity reactions.
Patients and methods
Patients
Patients eligible for participation in this study met the
following inclusion criteria: female, aged 18-65 years, with
histological proof of invasive adenocarcinoma of the breast;
a diagnosis of either progressive metastatic or locally
advanced disease; presence of at least one bidimensionally
measurable target lesion; a WHO performance status of 0 to
2; and a life expectancy of > 12 weeks. Normal biological
values were mandatory: adequate bone marrow function
(absolute neutrophil count >2000 mm-3, platelet count
> 100 000 mm-3), serum bilirubin < 1.25 x upper limit of
normal value (ULNV), serum creatinine < 120 mmol 1`,
AST <2 x ULNV or <3 x ULNV in the case of proven
liver metastases. Patients were not to have received prior
chemotherapy for advanced breast cancer, although
adjuvant chemotherapy was permitted provided there had
been a chemotherapy-free period of at least 12 months.
Previous hormonal therapy, either for initial or advanced
disease, was allowed; if a response to this treatment had
been obtained, a 6 week interval between treatments was
required. Radiotherapy was permitted unless it had involved
a site used to assess response, except in cases of subsequent
progression.
Exclusion criteria were as follows: pregnant and lactating
females; females of childbearing age unless using effective
contraception; previous malignancies, excluding curatively
treated in situ carcinoma of the cervix or non-melanoma
skin cancer; disease presence only in bone; previous bone
marrow transplantation; known metastases of the central
nervous system; symptomatic peripheral neuropathy >
grade 2 by the National Cancer Institute's common toxicity
criteria (NCI-CTC); other serious medical conditions;
concurrent treatment with other experimental drugs,
colony-stimulating factors, other anti-cancer therapy or
corticosteroids.
Study design and procedures
This was a phase II, multicentre, open-label, non-randomised
study conducted in France between 18 December 1992 and 15
December 1993.
Pretreatment investigations included medical history and
physical examination, chest radiograph, bone scan, liver
echography or computed tomography (CT) scan and ECG.
Thereafter, patients were treated with docetaxel (75 mg m-2)
in polysorbate 80 (diluted in 5% dextrose solution or 0.9%
saline) as an intravenous infusion over 1 h every 3 weeks on
an outpatient basis. Docetaxel was supplied by Rhone-
Poulenc Rorer Laboratory (Antony, France). No routine
prophylactic premedication for hypersensitivity reactions was
administered.
Treatment with docetaxel was scheduled to continue at the
same dose in patients showing a response until there was
evidence of disease progression or unacceptable toxicity.
However, if an adverse event occurred, the docetaxel dose
could be reduced, subject to the intensity of the event (NCI-
CTC criteria), to 55 mg m-2 at the next cycle and then by
25% of the previous dose if necessary, or the next cycle could
be delayed by up to 7 days. Patients showing no response
after three cycles were withdrawn and received alternative
treatment.
Patients were evaluable for efficacy if they had received
two or more treatment cycles. In the event of progression
before two cycles had been received (treatment failure),
patients were withdrawn and given alternative treatment.
Anti-tumour activity was evaluated every 6 weeks by serial
clinical, radiographic or CT measurements. The appearance
of any new lesions was noted, as were appreciable changes in
non-measurable lesions such as ascites or pleural effusions.
These data were used to determine objective response
categories according to WHO criteria [complete response
(CR), partial response (PR), no change (NC) or progressive
disease (PD)].
The best overall response (best response category achieved
between the start of docetaxel treatment and onset of
progression) was recorded for each patient. The time to
response, time to progression (dated from start oftreatment),
duration of response (dated from start of treatment in
responding patients) and duration of survival (dated from
start oftreatment) were also recorded. Patients were followed
every 3 months from study completion until death to
determine the overall survival time.
Thesafetyprofilewasevaluatedby 3 weeklymedicalhistory,
physical examination, vital sign assessment, WHO perfor-
mance status category evaluation, ECG, chest radiograph and
clinical chemistry determinations (alkaline phosphatase, LDH,
bilirubin, AST, ALT, serum creatinine, sodium, potassium,
magnesium, calcium, protein and albumin). In addition, a
neurological examination was performed before cycle 3. Blood
countswereperformedtwiceweeklyduringthefirstsixcyclesof
chemotherapy, and weekly thereafter. Adverse events arising
during each cycle were either spontaneously reported by the
patient or observed by the investigator. These were graded
according to NCI-CTC criteria. Patients were followed closely
for 1 month after their last dose ofdocetaxel to determine any
late adverse events.
Statistical methods
The number of patients to be enrolled was planned using a
modified two-stage Fleming design (Fleming, 1982; Simon,
1989). If at least one response was observed in the first 14
patients, an additional 16 patients were to be recruited. Seven
or more responses among 30 patients would be considered
promising. This procedure tests the null hypotheses that the
true tumour response rate is < 10% (i.e. docetaxel would be
of no further interest in breast cancer) vs the alternative, that
the true response rate is >30% (i.e. docetaxel is of
considerable interest). With 30 patients, the power of the
study at the 3% level of significance was 84.5%.Docetaxel for advanced breast cancer
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Continuous data were summarised as the median and
range, and 95% confidence intervals were calculated (Simon
1986). Duration of response and overall survival curves were
performed by the Kaplan-Meier method.
Two patient populations were defined for statistical
analysis: the intent-to-treat population which included all
patients who received at least one infusion of docetaxel; and
the population evaluable for response which included all
eligible patients who had received at least two cycles of
docetaxel therapy. All treated patients were analysed for
safety.
Results
Patients
Thirty-nine female patients with metastatic breast cancer,
aged between 36 and 65 years (median 51 years), were treated
with docetaxel. Patient and tumour characteristics at baseline
are summarised in Table I and show that patients recruited
were representative of the patient population with advanced
breast cancer. Thirteen (33%) of the 39 patients had more
than two metastatic sites and the majority of patients (72%)
had visceral involvement.
A total of 23 patients had received previous neoadjuvant
and/or adjuvant chemotherapy; of these, 19 (82.6%) patients
had received one previous regimen and four (17.4%) had
received two previous regimens. Anthracycline-containing
regimens had been given to 21 (91.3%) of these patients.
The median time between the last cycle of chemotherapy
and the start of docetaxel treatment was 31.1 months.
Three patients were retrospectively found to be ineligible
(liver enzymes >3 x ULNV; interval between end of
adjuvant chemotherapy and start of study <12 months;
previously treated for metastatic disease). Of 36 remaining
eligible patients, 31 were evaluable for efficacy. Reasons for
inevaluability were: concomitant radiotherapy for bone
metastasis; concomitant treatment with biphosphonates;
discontinuation of docetaxel after one cycle because of skin
reaction (no progression noted); discontinuation of docetaxel
during first infusion because of hypersensitivity reaction (no
progression noted); brain metastasis discovered 3 days after
first cycle. The baseline characteristics of the 31 evaluable
patients were similar to those of the intent-to-treat
population (see Table I).
Withdrawals
Ofthe 39 patients who received at least one dose ofdocetaxel
(intent-to-treat population), the most frequent reasons for
treatment discontinuation were disease progression (14
patients; 35.9%) and adverse events (18 patients; 46.2%).
One (2.6%) patient died during the study due to disease
progression (5.9%). Other reasons for withdrawal were
patients' refusal of treatment (four patients; 10.3%),
suspected but not confirmed disease progression (one
patient) and weakness (one patient).
Table I Patient and disease characteristics at baseline
Intent-to-treat
Patient characteristics
Number of patients
Age (years)
Median (range)
World Health Organization performance status
(no. of patients)
0
2
Tumour characteristics [no. of patients (%)]
Metastatic disease
Visceral metastases
Non-visceral metastases
Number of organs involved
1
2
>2
Predominant organs involved
Bone
Liver
Lymph nodes
Lung
Skin
Prior therapy
Prior chemotherapy [no. of patients (%)]
No
Yes
Previous anthracyclines
For adjuvant therapy alone
For neo-adjuvant therapy alone
For neo-adjuvant and adjuvant therapy
Prior hormonal therapy [no. of patients (%)]
No
Yes
For adjuvant therapy
For advanced disease
For adjuvant and advanced
Time from first diagnosis to first cycle of docetaxel (months)
Median (range)
39
51 (36-65)
21
14
4
39 (100)
28 (71.8)
11 (28.2)
10 (25.6)
16 (41.0)
13 (33.3)
18 (46.2)
16 (41.0)
16 (41.0)
11 (28.2)
9 (23.1)
16 (41.0)
23 (59.0)
21
14
4
4
20 (51.3)
19 (48.7)
11
4
4
36.1 (0.2-167.2)
31
50 (36-65)
18
9
4
31 (100)
21 (67.7)
10 (32.3)
10 (32.3)
11(35.5)
10 (32.3)
11(35.5)
10 (32.3)
12 (38.7)
10 (32.3)
9 (29.0)
11(35.5)
20 (64.5)
18
13
3
4
16 (51.6)
15 (48.4)
8
3
4
36.1 (0.2- 157.5)
EvaluableDocetaxel for advanced breast cancer
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Efficacy
The overall response rates to docetaxel treatment are
summarised in Table II. In the intent-to-treat population
(n = 39) there were four CRs (10.3%) and 15 PRs (38.5%) for
an overall response rate of 48.7% (95% CI 32-65%).
Among the 31 fully evaluable patients, four (12.9%) had a
CR and 12 (38.7%) had partial tumour regression, for an
overall response rate of 51.6% (95% CI 33-70%).
Analysis of the response in subgroups of patients was
carried out only in the evaluable patient population. In
evaluable patients with visceral involvement with or without
soft tissue and/or bone involvement docetaxel produced a
response rate of 52.4% (11 of 21 patients). High response
rates were noted in lung (66.7%), skin (57.1%), lymph nodes
(50%) and in the liver (44.4%). There was no major
difference in the response rate between patients with
previous adjuvant chemotherapy and those without any
previous chemotherapy (57% vs 46%).
The median time to first response was 12 (range 3 to 35+)
weeks. The median duration of response in all responders,
from the date of first docetaxel administration to the date of
documented progression, was 34 (range 11 to 42+) weeks.
The duration of complete response (calculated from the first
documentation of CR) ranged from 15 to 31 weeks in the
four patients with a CR. The median time to progression was
24 (range 0 to 42+) weeks, although five patients were still
responding at the study follow-up cut-off date. At the cut-off
date, the median follow-up time was 8 (range 7-12) months
and the median survival time had not been reached.
Tolerability
All 39 patients who received at least one cycle of docetaxel
therapy were evaluable for safety. The adverse events possibly
or probably related to docetaxel therapy which occurred in
this study are summarised in Table III. There were no deaths
associated with docetaxel-related adverse events.
Haematological adverse events Grade 4 neutropenia oc-
curred in 32 (82%) patients and 53% of cycles, but lasted
for more than 7 days in only four (3.5%) of 115 evaluable
cycles. Febrile neutropenia, defined as grade 4 neutropenia
concomitant with fever (>38°C) and requiring antibiotics
developed in only three (7.7%) patients and three (1.4%)
cycles. None of these episodes resulted in hospitalisation. No
cumulative haematological toxicity was observed.
Non-haematological adverse events The most frequently
reported non-haematological adverse events included asthe-
nia in 24 (61.5%) patients, nail disorders in 21 (53.8%)
patients, skin reactions in 20 (51.3%) patients and weight
gain in 18 (51.3%) patients. Alopecia was almost universal.
In the majority of cases, the adverse events were judged to be
mild or moderate in severity. Despite having received no
prophylactic premedication, only five (12.8%) patients
experienced acute hypersensitivity reactions and in only one
of these was the reaction severe (grade 3). Stomatitis was not
a significant problem in this study, the worst grade being 3 in
only one of the 39 treated patients. No severe nausea (grade
3) or vomiting (grade 3 or 4) occurred.
Fluid retention Fluid retention, defined as peripheral
oedema including facial oedema and/or effusions (pleural,
pericardial, ascites) and/or weight gain, was the most
frequently reported non-haematological adverse event.
Twenty-eight patients (71.8%) experienced fluid retention,
which was mild in 13 patients (33.3%), moderate in ten
patients (25.6%) and severe in five patients (12.8%).
Associated functional symptoms included walking impair-
ment (34.6% of patients), thirst (7.7%) and orthostatic
hypotension (3.8%).
The median time to onset of peripheral oedema was four
treatment cycles (median cumulative dose 227 mg m-2; range
1 + -527+).
Sixteen patients withdrew from treatment as a result of
fluid retention (including three patients with severe fluid
retention). Treatment discontinuation occurred after a
median cumulative dose of 592 mg m-2 (range 1+ -885+).
Following treatment discontinuation, fluid retention was
slowly reversible with a median time from last infusion to
resolution of symptoms of 18 weeks (range 3-29+).
Treatment adninistration
A total of 221 cycles were administered during the study; 209
cycles were given at the scheduled dose of 75 mg m-2
(94.6%) and 11 cycles at 55 mg m-2 (5%). Only one cycle
was delivered at a dose lower than 55 mg m-2; this was to a
patient who was withdrawn from the study owing to a severe
hypersensitivity reaction. Dose modification to 55 mg m-2
was necessary in three patients - for haematological
suppression in two patients and for non-haematological
toxicity in one patient. Treatment was delayed in eight
(20.5%) patients, but this was related to docetaxel in only
two patients. The median number of cycles received by each
patient was six (range 1-12), and the median dose received
was 74.6 mg m-2 (range 1.1-80.5). The median cumulative
dose was 436.4 mg m-2 (range 1.1-885.4). The median dose
intensity was 24.6 mg m 2 week '(range 0.4-25.6), giving a
median relative dose intensity of 0.98 (range 0.01 - 1.02).
Discussion
Previous clinical experience has shown that docetaxel
(100 mg m-2) every 3 weeks produces a high response rate
when used as first-line chemotherapy in patients with
Table II Overall response to docetaxel as first-line chemotherapy in patients with metastatic breast cancer
Intent-to-treat population (n= 39) Evaluable population (n=31)
Response No. (%) ofpatients 95% CI No. (%) ofpatients 95% CI
CR 4 (10.3) 4 (12.9)
PR 15 (38.5) 12 (38.7)
RR (CR+PR) 19 (48.7) 32-65 16 (51.6) 33-70
NC 11 (28.2) 10 (32.3)
PD 7 (17.9) 5 (16.1)
NE 2 (5.1)
Median (weeks) Range (weeks) Median (weeks) Range (weeks)
Time to first response 12 3-35+ 12 3-35+
Duration of response 34 11-42+ 34 11-42+
Time to disease progression 24 0-42+ 24 0-42+
Overall survival time NR - NR
CR, complete response; PR, partial respnse; RR, response rate; NC, no change; PD, progressive disease; NE, notevaluable; NR,endpointnotyet
reached; 95% CI, 95% confidence interval.Docetaxel for advanced breast cancer
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Table III Number (%) of patients experiencing adverse events during treatment with docetaxel (75mgm-2)
Overall incidence Incidence ofgrade 3 or 4 adverse event
Number of
Adverse event (by patients with Number of
NCI-CTC term) AE Percent ofpatients Percent of cycles patients Percent ofpatients
Haematological
Neutropenia 38 97 96 36 95
Thrombocytopenia 3 8 5 1 3
Anaemia 34 87 ND 5 13
Acute non-haematological
Hypersensitivity reaction 5 13 3 1 3
Local reaction 3 8 2 0 0
Nausea 19 49 17 0 0
Vomiting 8 21 7 0 0
Diarrhoea 10 26 6 0 0
Stomatitis 8 21 1 1 3
Febrile neutropeniaa 3 8 1 NA NA
Infection 0 26 10 0 0
Chronic non-haematological
Alopecia 38 97 ND NA NA
Skin reaction 20 51 ND 1 3
Neurosensory disorder 17 44 ND 1 3
Neuromotor disorder 1 3 ND 0 0
Weight gain 18 46 ND 1 3
Fluid retentionbc 28 72 ND 5d 13d
Nail disorderb 21 54 ND id 3d
Aestheniab 24 62 ND id 3d
aFebrile neutropenia defined as grade 4 neutropenia withconcomitant fever (>38'C) requiringhospitalisation and/or antibiotictherapy. bThese
are non-NCI-CTC terms. cIncludes oedema, effusions, ascites and otherwise unexplainable weight gain. dCategory 'severe'. NCI-CTC, National
Cancer Institute's common toxicity criteria; ND, data not available; NA, not applicable.
Table IV Response rates to docetaxel (75 or 100mgm72) by prognostic factor in evaluable patients
Response rate in evaluable patients
100mgm-2
75mgm-2 Chevallier et al. Seidman et al. Trudeau et al.
Prognosticfactor (present study) (1995)- (1993)- (1993)
Site of metastases
Liver 4/9 (44%) 12/16 (75%) 5/10 (50%) 13/25 (52%)
Visceral 11/21 (52%) 17/24 (71%) 13/26 (50%) 17/36 (47%)
Non-visceral 5/10 (50%) 4/7 (57%) 6/8 (75%) 7/11 (64%)
No. of organs involved
1 7/10 (70%) 9/11 (82%) 3/3 (100%) 3/8 (38%)
2 7/11 (64%) 8/11 (73%) 7/14 (50%) 7/16 (44%)
>2 2/10 (20%) 4/9 (44%) 9/17 (53%) 14/23 (61%)
aThese references contain preliminary results from the respective studies; the data presented in this table can be found in the respective Final
Medical Reports held on file at Rh6ne-Poulenc Rorer (data on file [5,6]).
advanced breast cancer [68%; 95% CI 49-83% (Chevallier
et al., 1995); 57%; 95% CI 31-83% (Seidman et al., 1993);
57%; 95% CI: 34-78% (Trudeau et al., 1993)]. However,
fluid retention may occur at this dosage, for which
prophylactic corticosteroid-based premedication may be
necessary. The present study was performed to examine the
efficacy and tolerability profile of docetaxel administered at a
reduced dosage of 75 mg m-2 every 3 weeks.
The overall response rate of52% (95% CI 33-70%) among
31 fully evaluable patients, including CR in 13%, confirms that
docetaxel at this dosage is still an active agent in this setting.
This response rate is at least equivalent to that reported in the
literature for doxorubicin (60 to 75 mg m-2) every 3 weeks as a
single agent in a similar patient setting (43%) (Henderson,
1991). Importantly, good response rates were achieved with
docetaxel in patients with visceral involvement (52%) and in
patients with multiple liver metastases (44%), the latter of
which is recognised as one of the most negative prognostic
factors in metastatic disease (Clark et al., 1987; Inoue et al.,
1991; Cheblowski et al., 1989). Furthermore, there were no
major differences in the response between patients who had
received previous adjuvant chemotherapy and those who had
not (54% vs 45%).
The 52% response rate achieved with docetaxel
(75 mg m-2) in the present study appears slightly lower
than those observed in studies ofdocetaxel (100 mg m-2) and
similar to those obtained in three Japanese studies in which
docetaxel (60 mg m 2) every 3-4 weeks produced an overall
response rate of 48% in a total of 183 evaluable patients
(data on file [1], Rhone-Poulenc Rorer). The apparent dose-
response relationship may be particularly marked in patients
with the poorest prognostic factors (Table IV). However,
bearing in mind the different patient populations, the small
numbers of patients involved and the overlapping confidence
intervals (data not shown), the suggestion of a dose-
response relationship for docetaxel remains to be confirmed
in prospective, comparative clinical trials.
The median duration of response (34 weeks) and time to
progression (24 weeks) achieved with docetaxel in the present
study are shorter than the 44 + and 37 + weeks, respectively,
reported with the 100 mg m-2 dosage in the other European
study (Chevallier et al., 1995). A smaller difference was
observed for median time to first response (12 vs 11 weeks),
although a more marked difference has been demonstrated in
a pooled analysis of 172 advanced breast cancer patients
treated with first-line docetaxel (75 or 100 mg m-2) [12 weeks
(range 3 -35 +) vs 9 weeks (range 2+ -29 +)] (data on file
[2], Rh6ne-Poulenc Rorer).Docetaxel for advanced breast cancer
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The acute adverse events associated with docetaxel
(75 mg m-2) in the present study (e.g. nausea and vomiting,
diarrhoea, stomatitis) are commonly seen with the majority
of the anti-cancer agents and were well tolerated by patients
in this study. No toxic deaths occurred.
Despite a high incidence of grade 4 neutropenia (82% of
patients, 53% of cycles), febrile neutropenia was observed in
only three patients, during three cycles, and none of these
required hospitalisation. No grade 3 or 4 infections were
observed. The discrepancy between a high incidence of grade
4 neutropenia and a lower incidence of its complications is
probably related to the short period of grade 4 neutropenia,
which lasted for more than 7 days in only 3.5% of cycles in
which it occurred. The severity of neutropenia was only
slightly higher in the earlier study of docetaxel (100 mg m-2)
(Chevallier et al., 1995): grade 4 neutropenia occurred in 91%
of 34 patients (69% of 177 treatmeni cycles). However, in the
same study, grade 4 neutropenia lasted for more than 7 days
in only 1 of 123 evaluable cycles (data on file [3], Rhone-
Poulenc Rorer) and no grade 3 or 4 infection was observed
during neutropenia.
Compared with docetaxel (100 mg m-2) (Chevallier et al.,
1995), fewer hypersensitivity reactions occurred in the present
study (29% vs 13%), despite the fact that no routine
premedication was used.
Fluid retention was the most frequently reported chronic
adverse event associated with docetaxel. This syndrome was
cumulative, non-life-threatening effect and it was slowly
reversible after treatment discontinuation (median time to
resolution 18 weeks). No cardiac, renal and endocrinological
disorders that might have been responsible for fluid retention
were observed. Recent data suggest that the pathophysiolo-
gical mechanism may be related to an increase in vascular
permeability (data on file [4], Rh6ne-Poulenc Rorer). Fluid
retention was a reason for study discontinuation in 16 (41%)
patients at a median cumulative dose of 592 mg m-2.
Nevertheless, 12 of these 16 patients showed a confirmed
objective response, indicating that the development of fluid
retention does not interfere with the anti-tumour response to
docetaxel. Furthermore, fluid retention was not associated
with any significant deterioration in performance status in
comparison with baseline measurements. The incidence of
fluid retention was similar in the present study and the earlier
study of docetaxel (100 mg m-2) (72% vs 77%), and led to
treatment discontinuation in a comparable percentage of
patients (41% with 75 mg m-2 and 50% with 100 mg m-2).
Likewise, the median cumulative dosage at treatment
discontinuation because of fluid retention was approximately
600 mg m-2 in both studies. Interestingly, the cumulative
dosage of docetaxel at onset of fluid retention was
approximately 100 mg m-2 lower with the 75 mg m-2
dosage than with the 100 mg m-2 dosage (227 mg m-2 vs
322 mg m-2), although this may be explained by the fact that
the investigators were more aware of the likelihood of
diagnosing oedema in the current study.
In conclusion, the results of this study of docetaxel, at a
dosage of 75 mg m-2 as a 1 h intravenous infusion every 3
weeks, confirm the efficacy of docetaxel as a first-line
chemotherapeutic agent for the treatment of patients with
metastatic breast cancer. Comparing the response rates in this
study with those reported with the usual dose of 100 mg m-2
in a similar study of first-line chemotherapy, it appears that
75 mg m-2 produces lower response rates than the higher
dosage (51.6% vs 67.7% respectively). Nevertheless, the anti-
tumour activity of docetaxel (75 mg m-2) appears similar to
that of first-line doxorubicin monotherapy at the recom-
mended dose of 60-75 mg m-2 (Henderson, 1991). The trend
in the dose-effect response with docetaxel still requires
further confirmation in prospective studies.
The incidence and severity of fluid retention were similar
in the present study of docetaxel (75 mg m-2) and the earlier
study of 100 mg m-2, but fewer hypersensitivity reactions
appeared to occur at the lower dosage. There is now some
evidence to suggest that prophylactic corticosteroid-based
premedication for hypersensitivity reactions and peripheral
oedema may be useful both in reducing the incidence and
severity of these events (Schrijvers et al., 1993; Valero et al.,
1994) and in delaying the onset of fluid retention. It is
possible that this strategy in combination with docetaxel
(100 mg m-2) will be preferable to a reduced docetaxel
dosage schedule for improving the safety profile of this
drug while retaining maximum response rates.
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